Abstract
Synopsis
Carvedilol is a β-adrenoceptor antagonist which also causes peripheral vasodilation primarily via α1-adrenergic blockade. Carvedilol produces its antihypertensive effect partly by reducing total peripheral resistance by blocking α1-adrenoceptors and by preventing β-adrenoceptor-mediated compensatory mechanisms. This combined action avoids many of the unwanted effects associated with traditional β-blocker or vasodilator therapy.
In clinical trials published to date, most of which enrolled small numbers of patients, the antihypertensive efficacy of carvedilol administered once daily was similar to that of atenolol, labetalol, pindolol, propranolol, metoprolol, nitrendipine (in elderly patients), slow release nifedipine or captopril in patients with mild-to-moderate essential hypertension. Combined therapy with carvedilol 25mg and hydrochlorothiazide 25mg, nicardipine 60mg or slow release nifedipine 20mg has an additive antihypertensive effect. Carvedilol and atenolol at similar doses were equally effective at reducing blood pressure in patients who had previously not responded adequately to hydrochlorothiazide monotherapy.
As a result of its multiple mechanisms of action, carvedilol is suited for the management of specific groups of hypertensive patients, such as those with renal impairment. In patients with non-insulin-dependent or insulin-dependent diabetes mellitus carvedilol does not appear to affect glucose tolerance or carbohydrate metabolism.
Initial studies have demonstrated that carvedilol and slow release nifedipine have similar efficacy in patients with stable angina pectoris and there is evidence that carvedilol has a beneficial haemodynamic effect in patients with congestive heart failure (NYHA class II or III) secondary to ischaemic heart disease.
A postmarketing surveillance study has shown that carvedilol is generally well tolerated with only 7% (164/2226) of patients (83% of the total number received 25mg daily for 12 weeks) withdrawing from treatment because of adverse events. Vertigo, headache, bronchospasm, fatigue and skin reactions were the most common events causing withdrawal.
Thus, clinical experience to date suggests that carvedilol is likely to be a valuable addition to the options currently available for treating patients with mild-to-moderate essential hypertension, and may offer particular benefit in specific populations of hypertensive patients.
Pharmacodynamic Properties
Racemic carvedilol is an arylethanolamine β-adrenoceptor antagonist with vasodilating properties. Antagonism of β1-adrenoceptor-mediated responses with carvedilol (demonstrated in various animal models and in healthy volunteers) is similar in potency, but longer lasting (15 to 16 hours) than that of propranolol (12 hours), and much greater in both potency and duration of effect than that of labetalol (1.5 hours). Some studies have shown that at a dose producing β1-blocking activity, carvedilol also antagonises β2-adrenoceptors but to a lesser extent, thus indicating weak selectivity for β1-adrenoceptors. However, other studies have failed to show any β2-adrenoceptor selectivity.
Antagonism of α1-adrenoceptors accounts for most of the vasodilatory activity of carvedilol, although at high concentrations (>1 μmol/L) antagonism of calcium channels has been observed consistently in various animal models. Although this does not appear to contribute to the antihypertensive effects of carvedilol, it may be of significance in specific vascular beds. Carvedilol exhibits no intrinsic sympathomimetic/partial agonist activity and only weak membrane-stabilising (local anaesthetic) activity.
Carvedilol has cardioprotective effects in animal models of acute myocardial infarction and is more effective in this regard than propranolol at comparable β-blocking doses. Carvedilol also protects against neuronal damage in in vitro and in vivo models of brain ischaemia and has antiproliferative effects in vascular smooth muscle in vitro.
Single oral doses of carvedilol as low as 12.5mg reduce resting and exercise blood pressure in healthy volunteers. In hypertensive patients carvedilol dose-dependently reduced mean diastolic blood pressure. Elderly hypertensive patients (aged > 65 years, baseline supine blood pressure 185/103mm Hg) respond equally well to carvedilol; a single 12.5mg dose adequately reduced mean peak supine blood pressure in many patients. Single doses of carvedilol 25mg and nitrendipine 20mg were equally effective.
Carvedilol generally has little or no effect on heart rate or cardiac index in healthy volunteers; however, cardiac output was reduced in exercising hypertensive patients treated with carvedilol, and the drug had less effect than propranolol or metoprolol on heart rate in resting or exercising hypertensive patients.
In patients with coronary artery disease, initial results show that carvedilol improved exercise capacity and left ventricular function and increased ejection fraction. There is also some evidence that left ventricular hypertrophy regresses in patients with hypertension treated with carvedilol and that the drug improves cardiac function in patients with idiopathic dilated cardiomyopathy.
Pharmacokinetic Properties
Carvedilol is rapidly absorbed when administered orally with maximum plasma concentrations (Cmax) reached 1 to 2 hours after single 25 or 50mg doses in healthy volunteers and hypertensive patients. Carvedilol undergoes extensive first-pass hepatic metabolism resulting in a low and variable absolute bioavailability of about 25%. The rate of absorption (as indicated by a slight increase in the time to reach maximum plasma concentrations), but not the extent of absorption, is decreased by food. Carvedilol is highly lipophilic and is widely distributed into extravascular tissues with a volume of distribution of 1.5 to 2 L/kg in healthy volunteers. Metabolism is primarily hepatic with less than 2% of a dose excreted unchanged in urine. Some metabolites appear to be active but whether this is of any clinical relevance is uncertain. Elimination is primarily biliary with 60% of a dose excreted in faeces. Thus, dosage adjustment in renally impaired patients is not required. However, peak plasma carvedilol concentrations and bioavailability are significantly increased in patients with severe hepatic impairment (e.g. cirrhosis) and the use of carvedilol in these patients is not recommended.
Therapeutic Efficacy
Data from clinical studies, analysed individually and combined in a meta-analysis, have conclusively demonstrated that carvedilol administered as a once daily 25mg dose has a significant antihypertensive effect in patients with mild-to-moderate essential hypertension. Indeed, a meta-analysis of 36 studies reported a decrease of 16/11mm Hg in mean systolic/diastolic blood pressures after 2 to 4 weeks of once daily (25mg) treatment in patients with a baseline blood pressure of 166/103mm Hg. No significant difference in antihypertensive effect was seen when carvedilol 50mg was administered daily as a single dose or as two 25mg doses. A 24-hour antihypertensive effect has been observed after once daily carvedilol administration in patients treated for 24 months.
Published studies to date comparing the antihypertensive effect of carvedilol with that of other agents have generally enrolled small numbers of patients and may not have had sufficient statistical power to detect potential differences between treatments. Nonetheless, these studies have shown that in hypertensive patients (generally treated for 4 to 12 weeks) once daily carvedilol 25 or 50mg had a similar effect to that of once daily pindolol 15mg, atenolol 50 to 100mg, hydrochlorothiazide 25mg, or nitrendipine 20mg (in elderly patients), or twice daily labetalol 200mg, propranolol 80mg, metoprolol 100mg, slow release nifedipine 20 to 40mg or captopril 25 to 50mg. In patients who had failed to respond sufficiently to hydrochlorothiazide therapy, the addition of carvedilol or atenolol produced a similar reduction in blood pressure after 6 weeks, with 67% of the carvedilol group and 71% of the atenolol group achieving a diastolic blood pressure ⩽ 90mm Hg. Other studies have demonstrated an additive antihypertensive effect when carvedilol 25mg and either hydrochlorothiazide 25mg, slow release nifedipine 20mg, or nicardipine 60 mg/day were given in combination. In small groups of hypertensive patients with concomitant disorders, carvedilol reduced blood pressure in those with renal failure and in patients with non-insulin-dependent diabetes, carvedilol 25mg once daily was as effective as nifedipine 10mg 3 times daily.
Compared with placebo, carvedilol increases exercise capacity and reduces myocardial oxygen consumption in patients with chronic stable angina pectoris and a 25mg dose administered twice daily has similar effects on total exercise time and time to 1mm ST-segment depression as slow release nifedipine 20mg administered twice daily. In addition, initial studies show that carvedilol 12.5 to 50mg twice daily has a beneficial effect (improved exercise time and resting left ventricular ejection fraction) in patients with chronic congestive heart failure (NYHA class II or III) secondary to ischaemic heart disease, although lower doses may be needed for safe initiation of therapy.
Tolerability
Results of a postmarketing surveillance study in 2226 patients treated with carvedilol for 12 weeks show that a daily 25mg dose administered as monotherapy is well tolerated by most patients. Treatment was withdrawn because of adverse events in 7% of patients; the most common adverse events responsible for withdrawal were vertigo (1.7%), headache (1.4%), bronchospasm (0.5%), fatigue (0.5%) and skin reactions (0.5%). Orthostatic hypotension has been reported in less than 1% of patients receiving carvedilol and has necessitated withdrawal of therapy in a few patients treated with a ⩾50mg daily dose.
Dosage and Administration
Most patients with mild-to-moderate hypertension respond to an oral carvedilol dose of 25mg administered once daily but if necessary this can be increased to 50 mg/day. All patients should initially receive 12.5mg daily for the first 2 days of therapy, and the maximum total daily dosage should not exceed 50mg. The recommended dosage for elderly hypertensive patients is 12.5mg once daily; this can be titrated (at intervals of 2 weeks) up to a maximum of 50 mg/day. In clinical studies, most patients with stable angina pectoris or congestive heart failure received 12.5 to 50 mg twice daily.
Carvedilol is not recommended for use in patients with hepatic dysfunction due to its increased bioavailability. Dosage adjustment is not necessary in patients with renal impairment.
Similar content being viewed by others
References
Abshagen U. A new molecule with vasodilating and β-adreno ceptor blocking properties. Journal of Cardiovascular Pharmacology 10 (Suppl. 11): S23–S32, 1987
Ajima H, Ota N, Igarashi S, Yamamura H. Phase I study of carvedilol (DQ-2466), a new β-blocker (The first report). The study of single oral administration. Japanese Journal of Clinical Pharmacology and Therapeutics 21: 391–400, 1990
Albergati F, Pateno E, Venuti RP, Boeri D, Lombardo I, et al. Comparison of the effects of carvedilol and nifedipine in patients with essential hypertension and non-insulin-dependent diabetes mellitus. Journal of Cardiovascular Pharmacology 19 (Suppl 1.): S86–S89, 1992
Bartsch W, Sponer G, Stren K, Müller-Beckmann B, Kling L, et al. Pharmacological characteristics of the stereoisomers of carvedilol. European Journal of Clinical Pharmacology 38: (Suppl. 2): S104–107, 1990
Bartsch W, Sponer G, Strein K, Müller-Beckmann B, Kling L, et al. Experimentelle Untersuchungen mit Carvedilol und Propranolol Zur Hämodynamik an Hunden und Zur Cardioprotektion an Ratten. In Bonelli & Hitzenberger (Eds) Beta-Rezeptoren Blockade, pp. (231–237), Symposium der Osterreichischen Arbeitsgemeinschaft für Klinische Pharmakologie, 1988
Beermann C, Schloos J, Belz GG. Oral administration of carvedilol and prazosin inhibits the prostaglandin F2α- and noradrenaline-induced contraction of human hand veins in vivo. Clinical Investigator 70: S13–S19, 1992
Belz GG, Beermann C, Schloos J, Neugebauer G. Influence of carvedilol on the responsiveness of human hand veins to noradrenaline and dinoprost. Drugs 36(Suppl. 6):69–74, 1988
Bril A, Slivjak M, DiMartino MJ, Feuerstein GZ, Linee P, et al. Cardioprotective effects of carvedilol, a novel eta-adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol. Cardiovascular Research 26: 518–525, 1992
Bristow MR, Larrabee P, Müller-Beckmann, Minobe W, Roden R, et al. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Clinical Investigator 70: S105–S113, 1992a
Bristow MR, Olson S, Gilbert EM, Larrabee PA, Volkman AK, et al. β-Blockade with carvedilol selectively lowers cardiac adrenergic drive in the failing human heart. Abstract. Journal of the American College of Cardiologists 19: 146A, 1992b
Cauchie P, Vanden Abeele C, Biemans M, Mattelaer P. A prospective postmarketing surveillance study of carvedilol in the management of hypertension in general practice. Abstract. Journal of Hypertension 10: 191, 1992
Cournot A, Lim C, Duchier J, Safar M. Hemodynamic effects of carvedilol after acute oral administration in hypertensive and normal subjects. Journal of Cardiovascular Pharmacology 19 (Suppl.1): S35–S39, 1992
Cubeddu LX, Fuenmayor N, Varin F, Villagra VG, Colindres RE, et al. Clinical pharmacology of carvedilol in normal volunteers. Clinical Pharmacology and Therapeutics 41: 31–44, 1987
DasGupta P, Broadhurst P, Raftery EB, Lahiri A. Value of carvedilol in congestive heart failure secondary to coronary artery disease. American Journal of Cardiology 66: 1118–1123, 1990
DasGupta P, Jain D, Lahiri A, Raftery EB. Long term efficacy and safety of carvedilol, a new β-blocking agent with vasodilating properties, in patients with chronic ischaemic heart disease. Drug Investigation 4: 263–272, 1992
de May C, Breithaupt K, Schloos J, Palm D, Belz GG. Extent and duration of carvedilol’s cardiovascular effects in relation to its α1- and β1-adrenergic radioreceptor kinetics. Abstract. 14th World Conference on Clinical Pharmacology and Therapeutics, Yokohama, July 26–31, 1992
Di Lenarda A, Gilbert EM, Olsen SL, Mealey PC, Bristow MR. Acute hemodynamic effects of carvedilol versus metoprolol in idiopathic dilated cardiomyopathy. Abstract. Journal of the American College of Cardiology 17: 142A, 1991
Dupont AG. Effects of carvedilol on renal function. European Journal of Clinical Pharmacology 38 (Suppl. 2): S96–S100, 1990
Dupont AG, Schoors DF, Venuti RP. The safety of adding carvedilol to hypertensive patients inadequately treated with diuretics. European Journal of Clinical Pharmacology 38 (Suppl. 2): S153–157, 1990
Dupont AG, Van der Niepen P, Taeymans Y, Ingels M, Piepsz A, et al. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension. Journal of Cardiovascular Pharmacology 10 (11): S130–136, 1987
Eggertsen R, Andrén L, Sivertsson R, Hansson L. Acute haemodynamic effects of carvedilol (BM 14190), a new combined beta-adrenoceptor blocker and pre-capillary vasodilating agent, in hypertensive patients. European Journal of Clinical Pharmacology 27: 19–22, 1984a
Eggertsen R, Sivertsson R, Andren L, Hansson L. Haemodynamic effects of carvedilol, a new beta-adrenoceptor blocker and precapillary vasodilator in essential hypertension. Journal of Hypertension 2: 529–534, 1984b
Eggertsen R, Sivertsson R, Andren L, Hansson L. Acute and long-term hemodynamic effects of carvedilol, a combined β-adrenoceptor blocking and precapillary vasodilating agent, in hypertensive patients. Journal of Cardiovascular Pharmacology 10 (Suppl.): S97–S100, 1987
Ehmer B, van der Does R, Rudorf J. Influence of carvedilol on blood glucose and glycohaemoglobin A1 in non-insulin-dependent diabetics. Drugs 36 (Suppl.): 136–140, 1988
Ehmer B, van der Does R, Rudorf J, Influence of carvedilol on blood glucose and glycohaemoglobin A1 in non-insulin-dependent diabetes. Drugs 36 (Suppl.): 136–140, 1988
Eichstäedt H, Schroeder RJ, Auffermann W, Richter W. Regression of left ventricular hypertrophy. Journal of Cardiovascular Pharmacology 19(Suppl.1): S55–S61, 1992
Engelmeier RS, O’Connell JB, Walsh R, Rad N, Scanion PJ, et al. Improvements in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 72: 536–546, 1985
Feuerstein GZ, Hamburger SA, Smith III EF, Bril A, Ruffolo Jr RR. Myocardial protection with carvedilol. Journal of Cardiovascular Pharmacology 19 (Suppl.1): S138–S141, 1992
Franz I-W, Agrawal B, Wiewel D, Ketelhut R. Comparison of the antihypertensive effects of carvedilol and metoprolol on resting and exercise blood pressure. Clinical Investigation 70: S53–S57, 1992
Freedman SB, Jamal SM, Harris PJ, Kelly DT. Comparison of carvedilol and atenolol for angina pectoris. American Journal of Cardiology 60: 49–502, 1987
Fujimaki M, Hakusui H, Hasegawa H. Assay and disposition of carvedilol enantiomers in humans and monkeys: evidence of stereoselective presystemic metabolism. Journal of Pharmaceutical Sciences 79 (7): 568–572, 1990a
Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O’Connell JB, et al. Long term β-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. American Journal of Medicine 88: 223–229, 1990
Goto Y, Tamachi H, Fusegawa Y, Nakaya N, Homma Y, et al. Effects of carvedilol on serum lipids in patients with essential hypertension. Journal of Cardiovascular Pharmacology 18 (Suppl.): S45–S50, 1991
Hakusui H, Fujimaki M. Pharmacokinetics of carvedilol in hypertensive patients with renal failure. Drugs 36 (Suppl.): 144–147, 1988
Hall S, Prescott RI, Hallman RJ, Dixon S, Harvey RE, et al. A comparative study of carvedilol, slow-release nifedipine, and atenolol in the management of essential hypertension. Journal of Cardiovascular Pharmacology 8 (Suppl.): S35–S38, 1991
Hamburger SA, Barone FC, Feuerstein GZ, Ruffolo Jr RR. Carvedilol (Kredex®)1 reduces infarct size in a canine model of acute myocardial infarction. Pharmacology 43: 113–120, 1991
Hattori Y, Nakaya H, Endou M, Nakao Y, Kanno M. Vascular effects of carvedilol, a new β-adrenoceptor antagonist with vasodilating properties, in isolated canine coronary artery. Journal of Cardiovascular Pharmacology 13: 572–579. 1989
Hauf- Zachariou U, Widmann, Zülsdorf B, Hennig M, Lang PD. Double-blind comparison of the effects of carvedilol and captopril on the lipid profile in patients with mild to moderate essential hypertension and dyslipidaemia. In press, 1993
Heber ME, Brigden GS, Caruana MP, Lahiri A, Raftery EB. Carvedilol for systemic hypertension. American Journal of Cardiology 59: 400–405, 1987
Hofferber E, Jacobitz P, Amah BI. Vasodilating β-receptor antagonists: comparison of labetalol, carvedilol, dilevalol and brefanolol. Naunyn-Schmedeberg’s Archives of Pharmacology 338 (Suppl.): R65, 1988
James IM, Yogendran L, McLaughlin K, Munro C. Blood pressure lowering and cerebral blood flow: a comparison of the effects of carvedilol and propranolol on the cerebral circulation in hypertensive patients. Journal of Cardiovascular Pharmacology 19 (Suppl. 1): S40–S50, 1992
Juttmann JR, de Vries Robles P, Venuti RP. Safety of the coadministration of carvedilol and nifedipine sustained-release in the treatment of essential hypertension. Journal of Cardiovascular Pharmacology 19 (Suppl. 1): S134–137, 1992
Kaski JC, Rodriguez-Plaza L, Rown J, Maseri A. Efficacy of carvedilol (BM14, 190), a new beta-blocking drug with vasodilating properties, in exercise-induced ischemia. American Journal of Cardiology 56: 35–40, 1985
Kawada T, Ishibashi T, Nakazawa M, Satoh S, Imai S. Adrenoceptor-blocking and cardiohemodynamic effects of carvedilol in animals. Journal of cardiovascular Pharmacology 16: 147–153, 1990
Kelly DT, Freedman SB. Multiple action compounds in angina pectoris. Zeitschrift für Kardiologie 78: 16–20, 1989
Kishida H, Saito T, Fukuma N, Hata N, Suzuki T. Evaluation of a new vasodilating β-blocking agent, carvedilol, in exertional angina using Holter monitoring. Japanese Heart Journal 31: 449–460, 1990
Kohno M, Takeda T, Ishii M, et al. Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension: An open, short term study. Drugs 36 (Suppl.): 129–135, 1988
Krämer BK, Ress KM, Erley CM, Risler T. Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure. European Journal of Clinical Pharmacology 43: 85–88, 1992
Krönig B, Widmann L, Staiger C, Machwirth M, Stienen U, et al. Blood-pressure-lowering effect of carvedilol vs nitrendipine in geriatric hypertensives. European Journal of Clinical Pharmacology 38 (Suppl.): S167–S170, 1990
Kuriyama Y, Nakamura M, Kyougoku I, Sawada T. Effects of carvedilol on cerebral blood flow and its autoregulation in previous stroke patients with hypertension. European Journal of Clinical Pharmacology 38 (Suppl. 2): S120–S121, 1990
Kuwahara M, Misu Y. Stereoselective antagonism by carvedilol against isoproterenol-induced facilitation of norepinephrine release in guinea-pig pulmonary arteries. Pharmacometrics 38 (e): 199–202, 1989
Lahiri A, Rodrigues EA, DasGupta P, Jain D, van der Does R, et al. Effects of carvedilol in patients with impaired left ventricular function due to ischaemic heart disease. Zeitschrift für Kardiologie 78 (Suppl.): 21–27, 1989
Lahiri A, Rodrigues EA, Al-Khawaja I, Raftery EB, Hinge D. Effects of a new vasodilating beta-blocking drug, carvedilol, on left ventricular function in stable angina pectoris. American Journal of Cardiology 59: 769–774, 1987
Lambert M, Luccioni R, Habib G, Simeoni JB, Rolland P, et al. Comparison of effectiveness and safety of carvedilol (25mg; once daily) versus labetalol (200mg twice daily) in patients with mild to moderate hypertension using an ambulatory 24 hours Holter monitoring. American Journal of Hypertension 4: 106A, 1991
Langdon CG, Baxter GA, Young PH. A multicenter comparison of carvedilol with hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension. Journal of Cardiovascular Pharmacology 18 (Suppl.): S51–S56, 1991
Leonetti G, Sempieri L, Cuspidi C, Boselli L, Terzoli L, et al. Resting and postexercise hemodynamic effects of carvedilol, a β-adrenergic blocker and precapillary vasodilator in hypertensive patients. Journal of Cardiovascular Pharmacology 10 (Suppl.): S94–S96, 1987
Louis WJ, McNeil JJ, Workman BS, Drummer OH, Conway EL. A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report. Journal of Cardiovascular Pharmacology 10 (Suppl.): S89–S93, 1987
Lund-Johansen P, Omvik P. Chronic haemodynamic effects of carvedilol in essential hypertension at rest and during exercise. European Heart Journal 13: 281–286, 1992
Lund-Johansen P, Omvik P, Nordrehaug JE, White W. Carvedilol in hypertension: Effects on hemodynamics and 24 hours blood pressure. Journal of Cardiovascular Pharmacology, 19 (Suppl. 1): S27–S34, 1992
Lysko PG, Lysko KA, Yue T-L, Gu J-L, Feuerstein G. Neuro-protective effects of carvedilol, a new antihypertensive, in cultured rat cerebellar neurons and in gerbil global brain ischemia. Stroke 23: 1630–1636, 1992
McPhillips JJ, Schwemer GT, Scott DI, Zinny M, Patterson D. Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A Dose Response study. Drugs 36 (Suppl.): 82–91, 1988
Mayer SE, Sanders-Bush E, Wells JN. Alpha- and beta-adrenergic blockade by carvedilol on vascular smooth muscle and brain phosphoinositide (PI) hydrolysis. FASEB Journal A326; 1988
McPhillips JJ, Schwemer GT, Scott DI, Zinny M, Patterson D. Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. Drugs 36 (Suppl.6): 82–91, 1988
Meyer-Sabellek W, Schulte K-L, Distler A, Gotzen R. Circadian antihypertensive profile of carvedilol (BM 14190). Journal of Cardiovascular Pharmacology 10 (Suppl.): S19–S123, 1987
Meyer-Sabellek W, Schulte K-L, Streitberg B, Gotzen R. Two-year follow-up of 24-hour indirect blood pressure monitoring: and open study. Drugs 36(Suppl 6): 106–112, 1988
Miki S, Masumura H, Kaifu Y, Yuasa S. Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension. Journal of Cardiovascular Pharmacology 18 (Suppl.): S62–S68, 1991
Monopoli A, Forlani A, Bevilacqua M, Vago T, Norbiato G, et al. Interaction of selected vasodilating β-Blockers with adrenergic receptors in human cardiovascular tissues. Journal of Cardiovascular Pharmacology 14: 114–120, 1989
Morgan TO, Snowden R, Butcher L. Effect of carvedilol and metoprolol on blood pressure, blood flow and vascular resistance. Journal of Cardiovascular Pharmacology 10 (Suppl.): S124–S129, 1987
Morgan TO, Anderson A, Cripps J, Adam W. The use of carvedilol in elderly hypertensive patients. European Journal of Clinical Pharmacology 38: S129–S133, 1990a
Morgan T, Anderson A, Cripps J, Adam W. Pharmacokinetics of carvedilol in older and younger patients. Journal of Human Hypertension 4: 709–715, 1990b
Moser M. Clinical experience with carvedilol. Journal of Human Hypertension 7 (Suppl. 1): in press, 1993
Moulds RFW, Stevens MJ, Lipe S, Medcalf RL, Iwanov V. Effects of carvedilol on human isolated blood vessels. Abstract. Journal of American College of Cardiologists 3: 566, 1984
Nahrendorf W, Rading A, Steinig G, van der Does R, Schlote A. A comparison of carvedilol with a combination of propranolol and isosorbide dinitrate in the chronic treatment of stable angina. Journal of Cardiovascular Pharmacology 19 (Suppl. 1): S114–S116, 1992
Neugebauer G, Akpan W, Kaufmann B, Reiff K. Stereoselective disposition of carvedilol on man after intravenous and oral administration of the racemic compound. European Journal of Clinical Pharmacology 38: S108–S111, 1990
Neugebauer G, Akpan W, von Möllendorff E, Neubert P, Reiff K. Pharmacokinetics and disposition of carvedilol in humans. Journal of Cardiovascular Pharmacology 10 (Suppl. 11): S85–S88, 1987
Neugebauer G, Gabor M, Reiff K. Pharmacokinetics and bio-availability of carvedilol in patient with liver cirrhosis. Drugs 36 (Suppl.): 148–154, 1988
Neugebauer G, Neubert P. Metabolism of carvedilol in man. European Journal of Drug Metabolism and Pharmacokinetics 16: 257–260, 1991
Nichols AJ, Gellai M, Ruffolo Jr RR. Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Fundamental and Clinical Pharmacology 5:25–38, 1991
Nichols AJ, Sulpizio AC, Ashton DJ, Hieble JP, Ruffolo RR. The interaction of the enantiomers of carvedilol with α1- and β1-adrenoceptors. Chirality 1: 265–270, 1989b
Nichols AJ, Sulpizio AC, Ashton DJ, Hieble JP, Ruffolo RR. In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol. Pharmacology 39: 327–336, 1989a
Ogihara T, Goto Y, Yoshinga K, et al. Dose-effect relationship of carvedilol in essential hypertension: an open study. Drugs 36 (Suppl.): 75–81, 1988
Ogihara T, Ikeda M, Goto Y, Yoshinaga K, Kumahara Y, et al. The effect of low dose carvedilol on circadian variation of blood pressure in patients with essential hypertension. Journal of Cardiovascular Pharmacology 10 (Suppl.): S108–S112, 1987
Ogihara T, Yoshinaga K, Yamahara Y, Ikeda M, Goto Y, et al. Clinical efficacy of carvedilol in severe hypertension. Journal of Cardiovascular Pharmacology 18: (Suppl.): S69–S72, 1991s
Ollivier JP, Durier P, Bussiere JL, Gayet JL. Safety and efficacy of once-daily carvedilol vs twice-daily labetalol in mild to moderate hypertension. European Journal of Clinical Pharmacology 38 (Suppl. 2): S1640–S166, 1990
Olsen SL, Gilbert EM, Renlung DG, Mealey PC, Volkman AK, et al. Carvedilol improves left ventricular function in idiopathic dilated cardiomyopathy. Abstract. Circulation 84 (Suppl. II): 11–564, 1991
Olsen SL, Yanowitz FG, Gilbert EM, Mealey PC, Volkman AK, et al. β-Blocker related improved in submaximal exercise tolerance in heart failure from idiopathic dilated cardiomyopathy (IDC). Abstract. Journal of the American College of Cardiology 19: 146 A, 1992
Omvik P, Lund-Johansen P. Acute haemodynamic effects of carvedilol in essential hypertension at rest and during exercise. European Heart Journal 12: 736–740, 1991
Omvik P, Lund-Johansen P, Myking O. Effects of carvedilol on atrial natriuretic peptide, catecholamines, and hemodynamics in hypertension at rest and during exercise. Journal of Cardiovascular Pharmacology 19 (Suppl. 1): S90–S96, 1992
Powell JR, Lahey A, Villegra VG, Cubeddu LX. Carvedilol pharmacokinetics after two intravenous doses. International Society of Hypertension. Abstract. 589, 1987
Reiff K. High-performance liquid Chromatographic method for the determination of carvedilol and its desmethyl metabolite in body fluids. Journal of Chromatography 413: 355–362, 1987
Rittinghausen R. Response rate with respect to the blood pressure-lowering effect of the vasodilating and β-blocking agent carvedilol. Drugs 36 (Suppl.6): 92–101, 1988
Rodeheffer RJ, Rommer JA, Wigley F, Smith CR. Controlled double-blind trial of nifedipine in the treatment of Raynaud’s phenomenon. New England Journal of Medicine 308: 880–883, 1983
Rodrigues EA, Lahiri A, Hughes LO, Kohli RS, Whittington JR, et al. Antianginal efficacy of carvedilol, a beta-blocking drug with vasodilating activity. American Journal of Cardiology 58: 916–921, 1986
Rudorf JE, Ehmer B. Pharmacokinetic and pharmacodynamic interactions of combined acute administration of carvedilol and hydrochlorothiazide in hypertensive volunteers. Drugs 36 (Suppl.): 113–117, 1988
Ruffolo Jr RR, Gellai M, Hieble JP, Willette RN, Nichols AJ. The pharmacology of carvedilol. European Journal of Clinical Pharmacology 38 (Suppl. 2): S82–S88, 1990a
Ruffolo Jr RR, Sauermelch Jr CF, Willette RN. Hemodynamic differences between carvedilol and labetalol in the cutaneous circulation. European Journal of Clinical Pharmacology 38 (Suppl. 2): S112–S114, 1990b
Ruffolo Jr RR, Boyle DA, Brooks DP, Feuerstein GZ, Venuti RP, et al. Carvedilol: a novel cardiovascular drug with multiple actions. Cardiovascular Drug Reviews 10: 127–157, 1992
Schnurr E, Widmann L, Glocke M. Efficacy and safety of carvedilol in the treatment of hypertension. Journal of Cardiovascular Pharmacology 10 (Suppl.): S101–S107, 1987
Seguchi H, Nakamura H, Aosaki N, Homma Y, Mikami Y, et al. Effects of carvedilol on serum lipids in hypertensive and normotensive subjects. European Journal of Clinical Pharmacology 38 (Suppl. 2): S139–S142, 1990
Seki N, Nagao T, Komori K, Suzuki H. Alpha and beta adrenoceptor blocking action of carvedilol in the canine mesenteric artery and vein. Journal of Pharmacology and Experimental Therapeutics 24 (3): 1116–1122, 1988
Senior R, Müller-Beckmann B, DasGupta P, van der Does R, Lahiri A. Effects of carvedilol on ventricular arrhythmias. Journal of Cardiovascular Pharmacology 19(Suppl. 1): S117–S121, 1992
Sievert H, Frey G, Schräder R, Schmidt T, van der Does R, et al. Influence of carvedilol and propranolol on coronary blood flow. European Journal of Clinical Pharmacology 38 (Suppl. 2): S122–S124, 1990
Smith III EF, Griswold DE, Hillegass LM, Slivjak MJ, Davis PA, et al. Cardioprotective effects of the vasodilator/beta-adrenoceptor blocker, carvedilol, in two models of myocardial infarction in the rat. Pharmacology 44: 297–305, 1992b
Smith III EF, Bril A, DiMartino MJ, Feuerstein G, Linee P, et al. Cardioprotective effects of carvedilol, a new beta adrenoceptor antagonist with vasodilating properties, in anaesthetized minipigs. Abstract. FASEB Journal 6: A1250, 1992a
Smith CD, McKendry RJR. Controlled trial of nifedipine in the treatment of Raynaud’s phenomenon. Lancet 2: 1299–1301, 1982
Sponer G, Bartsch W, Strein K, Müller-Beckmann B, Böhm E. Pharmacological profile of carvedilol as a β-blocking agent with vasodilating and hypotensive properties. Journal of Cardiovascular Pharmacology 9: 317–327, 1987a
Sponer G, Strein K, Müller-Beckmann B, Bartsch W. Studies on the mode of casodilating action of carvedilol. Journal of Cardiovascular Pharmacology 10 (Suppl. 11): S42–S48, 1987b
Stienen U, Meyer-Sabellek W. Hemodynamic and metabolic effects of carvedilol: a meta-analysis approach. Clinical Investigator 70: S65–S72, 1992
Sundberg S, Tiihonen K, Gordin A. Vasodilatory effects of carvedilol and pindolol. Journal of cardiovascular Pharmacology 10 (Suppl.): S76–S80, 1987
Sung C-P, Arleth AJ, Ohlstein EH. Carvedilol inhibits vascular smooth muscle cell proliferation. Journal of Cardiovascular Pharmacology, in press, 1993
Takabatake T, Ohta H, Yamamoto Y, Ishida Y, Hara H, et al. Combination therapy with carvedilol and nicardipine in essential hypertension. An open study. Drugs (Suppl. 6):124–128, 1988
Takeda T, Kohno M, Ishii M, Kubo S, Saruta T, et al. Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial. European Journal of Clinical Pharmacology 38 (Suppl. 2): S158–S163, 1990s
Tiedemann P, Peters P. Effects of carvedilol (BM 14.190) on haemodynamics and ventilation in healthy volunteers. 10th Scientific Meeting of the International Society of Hypertension. Interlaken, June 17–21, 1984
Tomita K, Yoshiyama N, Marumo F. Long-term effects of carvedilol on renal function in patients with essential hypertension. Presented at the International Symposium on Multiple Action Agents in Cardiovascular Therapy, Milan, Italy, June, 1991
Tomlinson B, Bompart F, Graham BR, Liu J-B, Prichard BNC. Vasodilating mechanism and response to physiological pressor stimuli of acute doses of carvedilol compared with labetalol, propranolol and hydrazine. Drugs 36 (Suppl.6): 37–47, 1988
Tomlinson B, Cronin CJ, Graham BR, Prichard BNC. Haemodynamics of carvedilol in normal subjects compared with propranolol, pindolol, and labetalol. Journal of Cardiovascular Pharmacology 10 (Suppl.): S69–S75, 1987
Valocik RE, Schnell MA, Mitchel MP, Kopaciewicz LJ, Hamburger SA. Carvedilol reduces myocardial damage caused by coronary occlusion in dogs (abstract A3926). Faseb J5, 1046, 1991
van der Does R, Eberhardt R, Derr I, Ehmer B, Rudorf J, et al. Treatment of chronic stable angina with carvedilol in comparison with nifedipine s.r. European Heart Journal 12: 60–64, 1991
van der Does R, Widmann L, Uberbacher H-J, Hörrmann M, Machwirth M, et al. Efficacy and safety of carvedilol in comparison with atenolol in hypertensive patients pretreated with hydrochlorothiazide. European Journal of Clinical Pharmacology 38 (Suppl.2): S147–S152, 1990
Varin F, Cubeddu LX, Powell JR. Liquid Chromatographic assay and disposition of carvedilol in healthy volunteers. Journal of Pharmaceutical Sciences 75 (12): 1195–1197, 1986
von Möllendorff E, Abshagen U, Akpan W, Neugebauer G, Schröter E. Clinical pharmacologic investigations with carvedilol, a new beta-blocker with direct vasodilator activity. Clinical Pharmacology and Therapeutics 39: 677–682, 1986
von Möllendorf T E, Reiff K, Neugebauer G. Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. European Journal of Clinical Pharmacology 33: 511–513, 1987
Wendt Th, van der Does R, Schräder R, Landgraf H, Kober G. Acute hemodynamic effects of the vasodilating and β-blocking agent carvedilol in comparison to propranolol. Journal of Cardiovascular Pharmacology 10 (Suppl): S147–S150, 1987
Why HJF, Richardson PJ. Effect of carvedilol on left ventricular function and mass in hypertension. Journal of Cardiovascular Pharmacology 19 (Suppl. 1): S50–S54, 1992
Widman L, van der Does R, Hörrmann M, Machwirth M. Safety and antihypertensive efficacy of carvedilol and atenolol alone and n combination with hydrochlorothiazide. European Journal of Clinical Pharmacology 38 (Suppl. 2): S143–S146. 1990
Woodward SA, Allen S, Boyle R, Dews I, Kimber S, et al. A comparison of the effect of carvedilol and nifedipine on the exercise capacity of patients with ischaemic heart disease. Abstract. British Journal of Clinical Pharmacology 25 (5): 658P, 1988
Yasujima M, Goto Y, Yoshinaga K, et al. Efficacy and tolerance of carvedilol in combination with a thiazide diuretic in the treatment of essential hypertension. An open study. Drugs 36 (Suppl.): 118–123, 1988
Young PH on behalf of the INT-CAR-07(UK) study group, A comparison of carvedilol with atenolol in the treatment of mild-to-moderate essential hypertension. Journal of Cardiovascular Pharmacology 19 (Suppl. 1): S82–S85, 1992
Yue T-L, Cheng H-Y, Lysko PG, McKenna PJ, Feuerstein R, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. Journal of Pharmacology and Experimental Therapeutics 263: 92–98, 1992b
Yue T-L, McKenna PJ, Lysko PG, Ruffolo Jr RR, Feuerstein GZ. Carvedilol, a new antihypertensive, prevents oxidation of human low density lipoprotein by macrophages and copper. Atherosclerosis 97: 209–216, 1992a
Author information
Authors and Affiliations
Additional information
Various sections of the manuscript reviewed by: S.A. Doggrell, Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand; A.G. Dupont, Department of Internal Medicine, Academisch Ziekenhuis — Vrije Universiteit Brussel, Brussels, Belgium; R. Eggertsen, Department of Medicine, Östra Hospital, Göteborg, Sweden; W.H. Frishman, Montefiore Medical Center, The Jack D. Weiler Hospital of the Albert Einstein College of Medicine, Bronx, New York, USA; Y. Hattori, Department of Pharmacology, Hokkaido University School of Medicine, Sapporo, Japan; J.C. Kaski, Department of Cardiological Sciences, St George’s Hospital Medical School, London, England; G. Leonetti, Centro Auxologico Italiano, Istituto di Ricovero e Cura a Carattere Scientifico, Milano, Italy; W.J. Louis, Clinical Pharmacology and Therapeutics Unit, Department of Medicine, University of Melbourne, Heidelberg, Victoria, Australia; T.O. Morgan, Department of Physiology, University of Melbourne, Heidelberg, Victoria, Australia; T. Ogihara, Department of Geriatric Medicine, Osaka University Medical School, Osaka, Japan; B.N.C. Prichard, Department of Clinical Pharmacology, University College and Middlesex School of Medicine, University College London, London, England; E.B. Raftery, Cardiology Research Department, Northwick Park Hospital, Harrow, Middlesex, England.
Rights and permissions
About this article
Cite this article
McTavish, D., Campoli-Richards, D. & Sorkin, E.M. Carvedilol. Drugs 45, 232–258 (1993). https://doi.org/10.2165/00003495-199345020-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199345020-00006